NASDAQ:AUPH

Aurinia Pharmaceuticals Competitors

$12.35
-0.25 (-1.98 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$12.34
Now: $12.35
$12.66
50-Day Range
$12.30
MA: $13.29
$14.58
52-Week Range
$12.01
Now: $12.35
$20.50
Volume1.44 million shs
Average Volume4.29 million shs
Market Capitalization$1.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.87

Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) Vs. TGTX, IONS, SRPT, PRGO, ALLK, and BPMC

Should you be buying AUPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aurinia Pharmaceuticals, including TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Allakos (ALLK), and Blueprint Medicines (BPMC).

TG Therapeutics (NASDAQ:TGTX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for TG Therapeutics and Aurinia Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TG Therapeutics00503.00
Aurinia Pharmaceuticals01702.88

TG Therapeutics currently has a consensus target price of $64.00, suggesting a potential upside of 39.37%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than TG Therapeutics.

Risk and Volatility

TG Therapeutics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Earnings & Valuation

This table compares TG Therapeutics and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$150,000.0041,969.61$-172,870,000.00($1.83)-24.47
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Aurinia Pharmaceuticals has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.7% of TG Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares TG Therapeutics and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TG Therapeutics-151,798.69%-223.96%-108.08%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Summary

Aurinia Pharmaceuticals beats TG Therapeutics on 8 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Ionis Pharmaceuticals and Aurinia Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
Aurinia Pharmaceuticals01702.88

Ionis Pharmaceuticals currently has a consensus target price of $57.9091, suggesting a potential upside of 42.00%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Ionis Pharmaceuticals has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ionis Pharmaceuticals and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Summary

Ionis Pharmaceuticals beats Aurinia Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Sarepta Therapeutics and Aurinia Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191302.52
Aurinia Pharmaceuticals01702.88

Sarepta Therapeutics currently has a consensus target price of $150.4762, suggesting a potential upside of 109.58%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Sarepta Therapeutics.

Volatility and Risk

Sarepta Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Sarepta Therapeutics and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.97$-715,080,000.00($9.71)-7.39
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Aurinia Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Sarepta Therapeutics and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Perrigo (NYSE:PRGO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Perrigo and Aurinia Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Aurinia Pharmaceuticals01702.88

Perrigo currently has a consensus target price of $52.00, suggesting a potential upside of 24.94%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Perrigo.

Volatility and Risk

Perrigo has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Perrigo and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.15$146.10 million$4.0310.33
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Perrigo has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Perrigo and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Summary

Perrigo beats Aurinia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Institutional and Insider Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 44.8% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Allakos and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-55.29
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Allakos has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Allakos is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Allakos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Allakos and Aurinia Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Aurinia Pharmaceuticals01702.88

Allakos currently has a consensus target price of $181.50, suggesting a potential upside of 73.68%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Allakos.

Profitability

This table compares Allakos and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Summary

Allakos beats Aurinia Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Earnings & Valuation

This table compares Blueprint Medicines and Aurinia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.96$-347,690,000.00($7.27)-13.09
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Aurinia Pharmaceuticals has lower revenue, but higher earnings than Blueprint Medicines. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Blueprint Medicines and Aurinia Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
Aurinia Pharmaceuticals01702.88

Blueprint Medicines presently has a consensus target price of $112.40, suggesting a potential upside of 18.07%. Aurinia Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Blueprint Medicines.

Profitability

This table compares Blueprint Medicines and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Summary

Blueprint Medicines beats Aurinia Pharmaceuticals on 9 of the 15 factors compared between the two stocks.


Aurinia Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78-2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50-3.5%$5.55 billionN/A-38.14Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40-1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52-2.2%$2.00 billion$103.54 million-19.19Insider Selling
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.